cfDNA Multi-Signal Analysis for Early Disease Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liquid biopsy methods for early disease detection, particularly in conditions like ovarian cancer, face challenges in providing sufficient spatial and temporal heterogeneity information and require a priori knowledge of tumor mutation spectra, limiting their effectiveness in detecting early-stage diseases.
Innovation Solution
A method combining analysis of cell-free DNA (cfDNA) methylation, nucleosome footprint, and copy number alteration (CNA) to enhance diagnostic performance, utilizing low-coverage sequencing data without requiring specific markers, and identifying disease-specific methylation markers through genome-wide analysis of cfDNA sequences.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If liquid biopsy methods use traditional marker detection approaches, then detection specificity is improved, but detection sensitivity for early-stage diseases deteriorates
Solution Approach 1:
The patent combines three distinct cfDNA analysis methods (methylation analysis, nucleosome footprint analysis, and copy number alteration analysis) into a unified diagnostic approach. Each method targets different biological characteristics of tumor-derived cfDNA, and their integration creates a composite diagnostic signal that overcomes the limitations of individual methods, enabling detection of early-stage cancers with both high sensitivity and specificity
Solution Approach 2:
The diagnostic system uses a composite analytical framework that processes multiple types of cfDNA biomarkers simultaneously. By analyzing methylation patterns, nucleosome positioning, and copy number variations together, the system creates a multi-dimensional diagnostic profile that enhances early cancer detection capability while maintaining robustness against false positives
2Measurement precision
If liquid biopsy methods require a priori knowledge of tumor mutation spectra, then detection precision is improved, but adaptability to different cancer types deteriorates
Solution Approach 1:
The patent develops a universal cfDNA analysis platform that can detect multiple cancer types without requiring cancer-specific prior knowledge. The three analytical methods (methylation, nucleosome footprint, and CNA) are fundamentally applicable across different tumor types, allowing the system to adapt to various cancers including ovarian, lung, and breast cancers using the same core methodology
Solution Approach 2:
The system dynamically adjusts analytical parameters based on the specific clinical context and sample characteristics. By modifying weighting factors, threshold values, and analysis priorities according to different cancer types and patient histories, the system maintains high detection precision while being adaptable to diverse clinical scenarios
3Reliability
If liquid biopsy analysis uses multiple cfDNA characteristics, then diagnostic performance is improved, but analysis complexity deteriorates
Solution Approach 1:
The patent divides the complex diagnostic process into three independent but complementary analytical modules: methylation analysis, nucleosome footprint analysis, and copy number alteration analysis. Each module processes specific aspects of cfDNA independently, then results are integrated through standardized algorithms. This segmentation reduces computational complexity while maintaining comprehensive diagnostic capability
Data Source
Figure 1A~1B
Figure 1C~1D
Figure 2(A)~2(B)
AI summary
Described are methods of analyzing cell free DNA based on combining analysis of cfDNA methylation with analysis of the cfDNA nucleosome footprint and/or with analysis of cfDNA copy number alteration. The diagnostic performance of these methods, in particular relating to early or earlier stage diseases or disorders, is increased compared to the diagnostic performance of the individual cfDNA analysis methods.